undamentalytics Newsletter
Sign in

Emergent Biosolutions Inc. cash flow statement

In fiscal 2025, Emergent Biosolutions Inc.'s operations generated $171m of cash; it spent $13.8m on capital projects, leaving free cash flow of $157m. It returned $24.9m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations3098124097112435520842188537320−34−20659171200
Depreciation and amortisation5691117222428323650501241431251099660
Stock-based pay5711111113161915232752424523181618
Capital spending332254544231457655728714222411652231412
Free cash flow−376−42−145582−2−22153−3010139596−150−25836157188
Free cash flow after stock pay−869−53−254469−18−40138−547434354−195−28118141170
Share buybacks—00600003300010682002527
Shares issued————————————00800—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EBS vs TVTXALVO vs EBSAMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Emergent Biosolutions Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Emergent Biosolutions Inc.